| SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device | 07/03 08:30 | globenewswire.com |
| SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology | 06/11 08:30 | globenewswire.com |
| SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company | 06/10 08:30 | globenewswire.com |
| Article in Nature Scientific Reports Describes Mechanism of Action of SeaStar Medical's Selective Cytopheretic Device in the Immunomodulation of Excessive Inflammation | 06/07 08:30 | globenewswire.com |
| SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024 | 06/06 16:05 | globenewswire.com |
| SeaStar Medical Announces 25-for-1 Reverse Stock Split | 06/06 08:30 | globenewswire.com |
| Manuscript Published on Multiorgan Failure Patients Treated with SeaStar Medical's Selective Cytopheretic Device Who Achieved Transplant Eligibility | 05/22 08:30 | globenewswire.com |
| Swiss National Bank Lowers Stock Position in ICU Medical, Inc. (NASDAQ:ICUI) | 05/20 04:42 | https://www.defenseworld.net |
| 1847 Reports 15.0% Increase in Revenue to $14.9 Million for the First Quarter of 2024 | 05/16 08:30 | accesswire.com |
| SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure | 04/30 08:30 | globenewswire.com |